NCT02183532已完成1 期
Pharmacokinetics of Single and Multiple Oral Doses of 5 mg BI 1356 in Healthy Chinese Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 12
- 主要终点
- AUCτ (Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ)
研究概览
简要总结
Study to investigate the pharmacokinetics of BI 1356 after single and multiple oral doses of 5 mg in Chinese healthy subjects
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male and female Chinese healthy volunteers who meet the criteria below:
- •Persons without clinically remarkable findings or clinically evident complications based on their concurrent illness, past medical history, physical examination, vital signs (blood pressure, pulse rate, and body temperature), 12-lead Electrocardiogram (ECG), and laboratory test results
- •Age ≥18 and Age ≤45 years
- •Body weight ≥50 kg with BMI ≥19 and BMI ≤24 kg/m2 (Body Mass Index)
- •Signed and dated written informed consent prior to admission to the study in accordance with Good clinical Practice (GCP) and the local legislation
排除标准
- •Persons who deviate from the norm, and who show clinical findings (Blood pressure (BP), Heart rate (HR), and ECG) on consultation
- •Persons with any clinically significant complications
- •Persons with gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immune, or hormonal disorders
- •Persons with central nervous system disorders (e.g., epilepsy), mental disorders, or neurological disorders
- •Persons with a history of significant orthostatic hypotension, syncopal attacks, or blackouts
- •Persons with chronic infection or severe acute infection
- •Persons with a history of severe allergy/hypersensitivity (including allergies to drugs or inactive ingredients)
- •Persons who will have received a drug with a long half-life (more than 24 hours) within the month before treatment in this study, within a period 10 times longer than the half-life of each drug, or during the study
- •Persons who will have received a drug that may theoretically affect the study results based on the information obtained at the time of preparation of the protocol, within the 10 days before treatment or during the study (e.g inhibitors or inducers of Pgp or CYP 3A4)
- •Persons who will have participated in another trial of an investigational drug within the 4 months before treatment or during the study
- •Smokers (who smoke more than 10 cigarettes, or 3 cigars, or 3 pipes per day)
- •Persons who cannot abstain from smoking throughout the study
- •Persons who undoubtedly abuse alcohol
- •Persons who abuse drugs
- •Persons who donate blood of 100 mL or more within the 4 weeks before treatment
- •Persons who perform rigorous exercise (within the week before treatment or during the study)
- •Persons with any laboratory test result outside the reference range and for whom the result is considered a clinically significant change
- •Persons who cannot obey the dieting rules of the study centre
- •Persons with any ECG value outside the reference range and who are of clinical importance. Examples include, but are not limited to, QRS interval >120 ms.
- •Pre-menopausal women (last menstruation <1 year prior to the date of informed consent) who:
- •are nursing or pregnant
- •or are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to periodic pregnancy testing during their participation in the trial. Acceptable methods of birth control include transdermal patch, intra uterine devices/systems (IUDs/IUSs), oral, implantable or injectable contraceptives, sexual abstinence and vasectomised partner. No exception will be made.
研究组 & 干预措施
BI 1356 BS
Experimental
干预措施: BI 1356 BS (Drug)
结局指标
主要结局
AUCτ (Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ)
时间窗: up to day 19
Cmax,ss (Maximum measured concentration of the analyte in plasma at steady state)
时间窗: up to day 19
次要结局
- Cmax (Maximum measured concentration of the analyte in plasma) at different time points after single and multiple doses(up to day 19)
- RA,Cmax (Accumulation ratio of the analyte in plasma after multiple dose administration over a uniform dosing interval τ) based on Cmax(up to day 19)
- RA,AUC (Accumulation ratio of the analyte in plasma after multiple dose administration over a uniform dosing interval τ) based on AUCτ(up to day 19)
- Number of patients with abnormal changes in laboratory parameters(up to 25 days)
- Number of patients with adverse events(up to 28 days)
- Number of patients with abnormal findings in physical examination(up to 25 days)
- Number of patients with clinically significant changes in 12-lead electrocardiogram (ECG)(up to 25 days)
- Vz/F (Apparent volume of distribution during the terminal phase λz following extravascular administration) at different time points after single and multiple doses(up to day 19)
- fet1-t2 (Fraction of analyte eliminated in urine from time point t1 to time point t2) at different time points after single and multiple doses(up to 168 h after first dose and up to 24 h after last dose)
- Cmin,ss (Minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ) for multiple doses(up to 144 h after last dose)
- PTF (Peak-Trough Fluctuation)(up to 120 h after first of multiple doses)
- Number of patients with clinically significant changes in Vital signs (blood pressure [BP], pulse rate [PR])(up to 25 days)
- CL/F (Apparent clearance of the analyte in plasma after extravascular administration) at different time points after single and multiple doses(up to day 19)
- Aet1-t2 (Amount of analyte that is eliminated in urine from time point t1 to time point t2) at different time points after single and multiple doses(up to 168 h after first dose and up to 24 h after last dose)
- AUCτ,ss (Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ)(up to 144 h after last dose)
- Cpre (Predose concentration of the analyte in plasma) at different time points(up to 120 h after first of multiple doses)
- tmax (Time from dosing to maximum measured concentration) at different time points after single and multiple doses(up to day 19)
- t1/2 (Terminal half-life of the analyte in plasma) at different time points after single and multiple doses(up to day 19)
- MRTpo (Mean residence time of the analyte in the body) at different time points after single and multiple doses(up to day 19)
- AUC0-infinity (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity after single dose administration)(up to day 7)
- AUC0-tz (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of last quantifiable analyte plasma concentration after single dose administration)(up to day 7)
- AUC0-24 (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 24 hours after single dose administration)(up to 24 h after single dose administration)
- AUC0-72 (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 72 hours after single dose administration)(up to 72 h after single dose administration)
- λz (Terminal rate constant in plasma) at different time points after single and multiple doses(up to day 19)
- Cavg,ss (Average concentration of the analyte in plasma at steady state)(up to 144 h after last dose)
- CLRt1-t2,ss (Renal clearance of the analyte at steady state from time point t1 to time point t2)(up to 144 h after last dose)
研究者
相似试验
已完成
1 期
Study to Explore Pharmacokinetics and Pharmacodynamics of a Single Rising Dose of BI 135585 XXHealthyNCT01652742Boehringer Ingelheim9
已完成
1 期
Effect of Multiple BI 1356 Doses of on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Female Premenopausal SubjectsHealthyNCT02175394Boehringer Ingelheim18
已完成
1 期
Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 Powder for Oral SolutionHealthyNCT01835899Boehringer Ingelheim24
已完成
1 期
The Effect of Multiple Oral Doses of BI 1356 BS on Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of Simvastatin and on the Pharmacokinetics of Its Metabolite Simvastatin Acid in Healthy Male VolunteersHealthyNCT02183623Boehringer Ingelheim20
已完成
1 期
Bioavailability of Warfarin After Coadministration With Multiple Doses of BI 1356 Compared to the Bioavailability of Warfarin Alone in Healthy Male VolunteersHealthyNCT02183389Boehringer Ingelheim18